Target Biology: What Is PTPRZ1?

PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1), also known as PTP-zeta or phosphacan, is a chondroitin sulfate proteoglycan and receptor-type phosphatase predominantly expressed in the central nervous system (CNS). It belongs to the type V subfamily of receptor-type protein tyrosine phosphatases (RPTPs).

PTPRZ1 plays essential roles in neural stem cell maintenance, oligodendrocyte differentiation, and axonal guidance. Its extracellular domain binds pleiotrophin (PTN) and midkine, growth factors that regulate cell migration and proliferation. Upon ligand binding, phosphatase activity is modulated, influencing downstream signaling cascades including those involving β-catenin and Erk/MAPK pathways.

Dysregulation of PTPRZ1 expression has been documented in multiple pathological contexts. Notably, PTPRZ1 is significantly overexpressed in glioblastoma multiforme (GBM) and has been identified as a marker of glioma stem cells, making it a target of active oncological research. Its role in tumor invasion, angiogenesis, and therapy resistance underscores its importance as an antibody target in both basic and translational neuroscience.

Antibody Specifications & Formulation

The PTPRZ1 Antibody (Cat. No. Ab351044) is supplied by Aladdin Scientific and is referenced under the supplier code absea#OC-359. The antibody is formulated in phosphate-buffered saline (PBS) only, without the addition of carrier proteins (such as BSA) or preservatives such as sodium azide.

This PBS-only formulation is advantageous for applications requiring direct conjugation, such as antibody labeling with fluorophores or enzymes, because the absence of exogenous proteins eliminates competition during conjugation reactions. Researchers should note that the absence of stabilizing carrier protein may require additional care during storage and handling to maintain antibody integrity.

Key specification highlights:

• Catalog Number: Ab351044
• Supplier Reference: absea#OC-359
• Formulation: PBS only
• Recommended Storage: -20°C, protect from light, avoid freeze-thaw cycles

For confirmed host species, clonality (monoclonal/polyclonal), immunogen details, reactivity, and validated applications, researchers are advised to consult the product datasheet available on the Aladdin Scientific website or contact technical support.

Recommended Applications & Sample Preparation

PTPRZ1 is a high-molecular-weight proteoglycan (the core protein alone exceeds 250 kDa), and its detection requires careful experimental design. While confirmed application data for Ab351044 should be verified on the product datasheet, antibodies targeting PTPRZ1 are commonly employed in the following assays:

• Western Blot (WB): Use SDS-PAGE gels optimized for high-molecular-weight proteins (3–8% Tris-acetate or 4–12% Bis-Tris gradient gels). Brain lysates and glioma cell lines (e.g., U87, U251) serve as positive controls.
• Immunohistochemistry (IHC): Formalin-fixed, paraffin-embedded (FFPE) brain tissue sections; antigen retrieval with citrate buffer (pH 6.0) is typically recommended.
• Immunofluorescence (IF): Applicable to fixed neural cell cultures and cryosections of CNS tissue.
• Immunoprecipitation (IP): Useful for co-IP studies of PTPRZ1 binding partners such as pleiotrophin.

Sample preparation tips: For WB, include protease and phosphatase inhibitor cocktails in lysis buffer to preserve PTPRZ1 phosphorylation state. Protein samples should be denatured under reducing conditions unless the epitope is conformation-sensitive. Extended transfer times or semi-dry transfer at low voltage are recommended for large proteins.

Troubleshooting Common Experimental Issues

Given PTPRZ1's large size and tissue-restricted expression, researchers may encounter specific technical challenges. The following troubleshooting guidance addresses the most frequently reported issues:

• No signal on Western blot: Confirm that the gel percentage is appropriate for proteins >200 kDa. Ensure transfer efficiency using a pre-stained molecular weight marker. Verify that the correct tissue or cell line is used as a positive control (e.g., brain tissue or glioblastoma cell lines).
• High background: Optimize blocking conditions by increasing blocking time (1–2 hours) with 5% non-fat dry milk or BSA in TBST. Titrate primary antibody concentration. For IHC, ensure endogenous peroxidase is quenched adequately.
• Non-specific bands: Consider increasing wash stringency (number and duration of TBST washes). Verify antibody dilution. If available, use a PTPRZ1-knockout cell lysate as a negative control to confirm band specificity.
• Weak signal in IHC: Optimize antigen retrieval conditions. If using FFPE tissue, ensure adequate deparaffinization. Extend primary antibody incubation to overnight at 4°C.
• PBS-only formulation handling: Because the antibody contains no carrier protein, avoid repeated freeze-thaw cycles. Prepare single-use aliquots upon receipt. Do not dilute to extremely low concentrations without adding a stabilizer such as 0.1% BSA if long-term storage of diluted antibody is required.